ERBB2 and breast carcinoma: While the effects of aCT1 on inflammation in breast cancer have not been directly explored, prior work has shown that aCT1 enhances the activity of tamoxifen on ER-positive breast cancer cells, and lapatinib on HER2-positive breast cancer cells [111].